1. Home
  2. SBI vs SCLX Comparison

SBI vs SCLX Comparison

Compare SBI & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Intermediate Muni Fund Inc

SBI

Western Asset Intermediate Muni Fund Inc

HOLD

Current Price

$7.94

Market Cap

111.7M

Sector

Finance

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$8.61

Market Cap

90.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBI
SCLX
Founded
1992
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
111.7M
90.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SBI
SCLX
Price
$7.94
$8.61
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
39.5K
80.8K
Earning Date
01-01-0001
11-14-2025
Dividend Yield
4.52%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$40,360,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$749.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.96
$3.60
52 Week High
$8.00
$34.27

Technical Indicators

Market Signals
Indicator
SBI
SCLX
Relative Strength Index (RSI) 67.87 33.95
Support Level $7.71 $7.82
Resistance Level $7.94 $10.41
Average True Range (ATR) 0.05 1.02
MACD 0.01 0.04
Stochastic Oscillator 95.83 18.77

Price Performance

Historical Comparison
SBI
SCLX

About SBI Western Asset Intermediate Muni Fund Inc

Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: